US Earnings Financial Results SEC Filings — March 19, 2026

19-03-2026

The 10-K filing includes Regulation AB Item 1122(d) servicing compliance assessments for asset-backed securities servicers Midland, PBLS, the Company, and CoreLogic, detailing which criteria each performs directly, via responsible vendors, subservicers, or not at all. Compliance is affirmed across most applicable criteria with some marked N/A or not performed by specific entities, such as back-up servicer requirements or certain investor reporting sub-items. No material deficiencies, exceptions, or financial impacts are disclosed.

19-03-2026

DarioHealth Corp. reported total revenues of $22.4M for FY 2025, down 17% YoY from $27.0M, driven by a 26% decline in services to $14.9M despite an 8.5% increase in consumer hardware to $7.4M. Operating expenses fell 31% to $49.3M, resulting in a smaller operating loss of $36.7M versus $57.7M prior year, and net loss improved slightly to $41.7M from $42.7M; however, cash and equivalents dropped to $21.8M from $27.8M, total assets declined to $110.1M from $118.9M, and stockholders' equity decreased to $67.9M from $72.0M amid significant share dilution to 6.9M shares outstanding.

• ·Cash used in operating activities improved to $(25.9M) from $(38.6M) YoY.
• ·Non-GAAP adjusted loss improved to $(24.2M) from $(33.8M), a $9.6M betterment.
• ·Accumulated deficit worsened to $(452.1M) from $(390.3M).
• ·Basic and diluted loss per share improved to $10.12 from $12.27.
• ·Weighted average shares increased to 3,983K from 2,452K.

19-03-2026

Republic Airways Holdings Inc. reported FY2025 revenues of $1,676.5M, up 13.7% YoY from $1,474.0M, with operating income rising 22.8% to $168.3M and Adjusted EBITDA surging 32.9% to $341.7M, driving net income to $76.2M (+18.0%). However, executive separation and merger-related costs jumped to $47.1M from $3.2M, total liquidity declined 1.1% to $319.9M, and net cash used in investing activities ballooned to $350.9M. In FY2024 vs FY2023, revenues grew modestly 3.1% but Adjusted EBITDA fell 12.8% to $257.2M.

• ·Net cash provided by operating activities increased 42.4% to $322.0M in FY2025 from $226.1M.
• ·Net cash used in investing activities worsened to $350.9M in FY2025 from $105.5M.
• ·Income tax expense rose 66.8% to $37.2M in FY2025.
• ·Depreciation and amortization increased 7.9% to $126.3M in FY2025.
• ·Marketable securities declined 15.3% to $162.2M in FY2025.

19-03-2026

Artius II Acquisition Inc., a SPAC, reported net income of $136k for the year ended December 31, 2025, compared to a $85k net loss for the period from inception (July 25, 2024) through December 31, 2024, driven by $8.1M interest income from the Trust Account offsetting a $7.9M operating loss that included a $6M advisory fee. Total assets grew to $228.3M primarily from $228.1M in the Trust Account following the IPO of 22M Class A shares, but shareholders' deficit widened significantly to $13.8M due to accretion of $18.8M. Cash position was minimal at $32k.

• ·IPO involved sale of public units generating $219.75M net proceeds.
• ·Founder shares: 250,000 Class B shares forfeited by Sponsor.
• ·Promissory note to related party repaid $135k in 2025.
• ·Basic and diluted EPS of $0.01 for redeemable and non-redeemable Class A shares in 2025.
• ·Class B shares EPS not applicable in 2025; prior period loss per share ($0.02).

19-03-2026

Rice Acquisition Corp 3, a SPAC, reported net income of $2.85M for the period from inception (June 6, 2025) to December 31, 2025, driven by $3.4M interest income from the Trust Account offsetting a $548K operating loss from formation and administrative costs. Total assets stood at $351.3M, primarily $348.4M cash in the Trust Account from IPO proceeds (34.5M Class A shares at $10.10 redemption value), while shareholders' deficit was $13.2M due to accretion and transaction costs. No business combination has occurred, with cash outside trust at $2.6M and ongoing liabilities including $13.4M deferred underwriting fees.

• ·IPO-related financing: $338.1M proceeds from Units net of underwriting discounts; $10.65M from Private Placement Warrants
• ·Cash flows: Net used in operations $(467.5K); investing $(345M) into Trust; financing $348.1M
• ·Non-cash: Accretion of Class A shares to redemption $28.9M; transaction costs allocated $257K

19-03-2026

Micron Technology reported exceptional Q2 FY2026 results with revenue surging 196% YoY to $23.9B from $8.1B, gross margin expanding dramatically to $17.8B (499% YoY increase), and net income skyrocketing 771% YoY to $13.8B. For the six months ended February 26, 2026, revenue more than doubled 124% YoY to $37.5B with net income up 451% to $19.0B. The balance sheet strengthened significantly, with cash and equivalents rising 44% to $13.9B, total assets up 23% to $101.5B, and long-term debt reduced 32% to $9.6B, though inventories dipped slightly 1% QoQ.

• ·EPS diluted Q2 FY2026: $12.07 (vs $1.41 YoY, +756%)
• ·R&D expense Q2: $1.25B (up 39% YoY)
• ·Stock-based compensation expense six months: $599M
• ·Dividends declared Q2: $0.115 per share ($132M total); six months $0.23 per share ($264M total)
• ·Several senior notes repaid in period including 2028 Notes, 2029 A/B Notes, 2029 Term Loan A, 2030 Notes (October 2025/February 2026)

19-03-2026

Lithium Americas Corp. (LAC) reported a widened net loss of $86.3M for the year ended December 31, 2025, compared to $42.6M in 2024, with net loss attributable to stockholders rising to $122.1M from $42.5M, driven by higher G&A expenses ($52.8M vs. $28.1M, +88%) and transaction costs ($32.3M vs. $22.2M, +45%), despite a $160M gain on warrant obligations offset by a $171M loss on convertible debt. Balance sheet growth was robust with cash and restricted cash up 52% to $905.6M, total assets more than doubling to $2.58B from $1.04B, and mineral properties, plant & equipment surging to $1.34B from $399M amid $765M investing outflows. However, total liabilities ballooned nearly 10-fold to $992.4M from $99.6M due to new DOE loan ($351M), convertible debt ($160M), and warrant obligations.

• ·Net cash provided by financing activities: $1,137.6M in 2025 vs. $589.1M in 2024 (+93%).
• ·Proceeds from public offerings: $401.2M in 2025.
• ·Proceeds from non-controlling interest: $100M in 2025 (Lithium Nevada Ventures LLC).
• ·Non-controlling interest increased to $527.9M from $310.3M.
• ·Weighted average shares outstanding: 243,658 (2025) vs. 200,817 (2024).

19-03-2026

Pelthos Therapeutics Inc. reported total revenue of $16.8M in 2025, up from $0 in 2024, driven by $16.2M in net product revenues and $0.6M in license revenues following apparent acquisitions. However, operating expenses surged 550% to $49.2M, primarily due to SG&A expenses rising over 6x to $42.5M, resulting in an operating loss widening to $32.4M from $7.6M and net loss expanding to $43.3M from $8.0M. Total assets grew dramatically to $130.4M from $1.4M, supported by $45.3M in financing cash inflows, though operating cash use increased to $22.6M.

• ·Cash and cash equivalents increased to $18.0M from $0.5M as of Dec 31 2025.
• ·Inventory net at $23.6M and accounts receivable $8.9M as of Dec 31 2025.
• ·Convertible debt $31.4M as of Dec 31 2025.
• ·Weighted average exercise price of outstanding options, warrants and rights: $5.95.
• ·Equity compensation plans remaining available: 354,497 securities.

19-03-2026

Accenture plc reported revenues of $18.0B for the three months ended February 28, 2026, up 8.3% YoY from $16.7B, and $36.8B for the six months ended February 28, 2026, up 7.1% YoY from $34.3B, with operating income rising 11.1% to $2.5B in Q2 and 3.3% to $5.4B for H1. However, net income attributable to Accenture plc increased only 2.1% to $1.8B in Q2 but declined 0.8% to $4.0B for H1 YoY, and cash and cash equivalents fell to $9.4B from $11.5B at August 31, 2025 amid heavy share repurchases and acquisitions. Diluted EPS rose modestly to $2.93 in Q2 (+3.9% YoY) and $6.47 for H1 (+0.8% YoY).

• ·Net cash provided by operating activities for six months: $5.48B, up from $3.88B YoY.
• ·Goodwill increased to $24.58B from $22.54B, reflecting acquisitions.
• ·Treasury shares at cost: ($11.0B) as of Feb 28, 2026, up from ($7.75B).
• ·Cash dividends per Class A share: $1.63 for three months, $3.26 for six months.

19-03-2026

Chicago Atlantic BDC, Inc. (LIEN) grew its investment portfolio to $333.3M at fair value as of December 31, 2025, up from $275.2M in 2024, driven by $156.2M in purchases, while total investment income surged 150% to $54.3M. However, net operating expenses rose 73.8% to $21.2M amid sharp increases in incentive fees (+256.9%) and management fees (+262.5%), and the stock traded at persistent discounts to NAV, ranging from -4.8% to -26.6% across 2025 quarters. Quarterly dividends held steady at $0.34 per share throughout 2025, up from $0.25 in 2024.

• ·Unrealized appreciation net $207,930 in 2025 vs $246,004 in 2024 (slight decline).
• ·Beginning portfolio $54.1M Dec 31, 2023 grew to $275.2M in 2024 via $240.5M purchases.
• ·Stock price low discount peaked at -43.8% in Q1 2024.
• ·Excise tax expense declined 39.7% to $72,406 in 2025.

19-03-2026

Neuraxis reported net sales growth of 32.9% YoY to $3.57M for the year ended December 31, 2025, from $2.69M in 2024, with gross profit rising 29.4% to $3.01M, reflecting strong gross margins around 84%. However, operating loss widened 9.4% to $7.83M due to sharp increases in selling expenses (+55.2%) and other costs, though net loss improved slightly by 5.3% to $7.80M. Cash and equivalents grew to $4.97M from $3.70M, supported by financing activities.

• ·Accounts receivable declined 20% to $195,703 as of Dec 31, 2025.
• ·Inventories increased to $257,132 from $44,328 YoY.
• ·Total assets grew to $6.40M from $4.76M.
• ·Net cash used in operations increased to $6.43M from $6.10M.

19-03-2026

Aebi Schmidt Holding AG reported sales of $1.53B for 2025, up 41% YoY from $1.09B, driven by strong North America growth (+64% to $975M) while Europe and ROW grew modestly (+12% to $552M). Adjusted EBITDA rose 34% to $133M (8.7% margin, down slightly from 9.1%), but net income fell 68% to $9.7M due to higher operating expenses (+45%), interest expense (+23%), and other losses. Operating cash flow dropped sharply 87% to $9M, though cash and equivalents increased 51% to $99M.

• ·Gross profit increased 33% to $304M, but cost of products sold rose 43%.
• ·Operating expenses up 45% to $231M, driven by SG&A (+45%) and amortization (+66%).
• ·Income from continuing operations before taxes down 73% to $11M.
• ·Net cash from investing activities $6M (vs -$9M prior), financing $16M (vs -$35M prior).

19-03-2026

Galera Therapeutics reported a net income of $149M for 2025, a dramatic turnaround from a $19M loss in 2024, driven by a $151M gain on debt extinguishment and $3.5M gain on sale of dismutase mimetics assets, alongside sharp declines in R&D (-89% YoY to $0.3M) and G&A expenses (-48% YoY to $5.7M). However, the company still posted an operating loss of $2.5M, with net cash used in operations improving to $6M from $12M but cash and equivalents declining to $6.4M from $8.3M, signaling ongoing cash burn despite reduced spending.

• ·Royalty purchase liability extinguished at $151M upon asset sale.
• ·Stockholders’ equity turned positive to $4.0M from ($148.0M) deficit.
• ·Net income per common share $0.64 vs ($0.34) in 2024.
• ·Proceeds from private placement $0.6M in 2025 vs $2.2M in 2024.

19-03-2026

Acrivon Therapeutics reported a narrower net loss of $77.9M for the year ended December 31, 2025, compared to $80.6M in 2024, primarily due to reduced operating expenses including R&D down 6% to $60.0M and G&A down 4% to $24.1M. However, total assets declined 34% to $129.7M from $196.6M, driven by a 45% drop in short-term investments to $77.1M and ongoing cash usage, while stockholders' equity fell 36% to $112.5M with no significant financing inflows. Liquidity remained strained as net cash used in operating activities was $63.7M, slightly improved from $65.7M.

• ·Net loss per share improved to $(2.02) from $(2.38).
• ·Accumulated deficit increased to $(274.9M) from $(197.0M).
• ·No new equity financing in 2025 after $123.8M raised via private placement and pre-funded warrants in 2024.
• ·Investing activities provided $66.1M cash in 2025 (from investment maturities) vs used $51.8M in 2024.

19-03-2026

Mount Logan Capital Inc. (MLCI) reported total revenues of $53.6M for the year ended December 31, 2025, up 8% YoY from $49.8M, driven by 17% growth in Insurance Solutions to $40.6M, while Asset Management revenues declined 14% to $13.0M with management fees down 14% and incentive fees down 50%. However, total expenses surged 102% to $120.6M due to a $25.5M goodwill impairment, 337% higher transaction costs, and 84% increase in Asset Management expenses, leading to a net loss of $60.8M versus a $10.4M loss in 2024; segment income fell to $8.5M from $22.8M.

• ·Restricted cash declined to $10.0M from $15.7M as of Dec 31, 2025 vs 2024.
• ·Cash from operating activities improved to -$22.2M from -$37.8M.
• ·Cash from investing activities was +$50.9M vs -$26.5M.
• ·Investments stood at $639.2M as of Dec 31, 2025, up slightly from $637.0M.

19-03-2026

Sprinklr reported FY2026 total revenue of $857.2M, up 8% YoY from $796.4M, driven by 29% growth in professional services to $100.9M while subscription revenue grew modestly 5% to $756.3M. Operating income improved to $40.2M from $24.0M, supported by a 10% decline in sales and marketing expenses to $287.6M and flat G&A, but net income dropped sharply to $22.9M from $121.6M due to a $43.9M tax provision versus a prior benefit. Gross margins deteriorated with subscription at 76% (down from 80%) and total costs of revenue up 26% YoY.

• ·Subscription revenue mix decreased to 88% of total revenue from 90% YoY.
• ·R&D expense up 5% YoY to $96.0M (11% of revenue).
• ·Total operating expenses declined to 63% of revenue from 69% YoY.
• ·Other income net stable at $26.6M.

19-03-2026

Rubrik reported total revenue of $1.32B for FY2026 (ended Jan 31, 2026), up 48% YoY from $887M, driven by 53% growth in subscription revenue to $1.26B, with gross profit surging 70% to $1.05B and free cash flow turning strongly positive at $238M versus $22M prior year. However, the company still posted a net loss of $349M, improved from $1.15B but reflecting high operating expenses of $1.40B, while other revenue declined 10% YoY to $52M and Subscription ARR Contribution Margin was a modest 12% despite improvement from 2%.

• ·Stock-based compensation expense declined to $329M in FY2026 from $914M in FY2025.
• ·Operating expenses decreased to $1.40B in FY2026 from $1.75B in FY2025.
• ·Subscription ARR Contribution improved to $169M in FY2026 from $23M in FY2025.

19-03-2026

Satellogic Inc. reported revenue growth of 38% YoY to $17.7M for FY 2025, driven by strong North America performance (+53% to $12.1M), with modest gains in Europe (+6% to $2.8M) and Asia (+8% to $2.5M), though South America grew from a low base. Total costs and expenses fell 25% to $48.7M, improving operating loss by 41% to $31.0M and slashing net loss to $4.8M from $116.3M; however, the company remains unprofitable with negative adjusted EBITDA of $17.4M and negative free cash flow of $34.3M.

• ·Net cash provided by financing activities increased to $112.5M in FY 2025 from $37.5M in FY 2024.
• ·Engineering expenses declined 28% YoY to $10.4M.
• ·Stock-based compensation in SG&A rose 84% to $3.7M.

19-03-2026

Snail, Inc. reported net revenues of $81.2M for the year ended December 31, 2025, down 3.8% YoY from $84.5M, with gross profit declining 25.8% to $22.4M due to higher cost of revenues (+8.4%) and sharply increased operating expenses (+50.7% to $39.7M), resulting in an operating loss of $17.3M versus a $3.9M profit in 2024. However, bookings grew 16.2% YoY to $87.8M. The filing highlights heavy reliance on the ARK franchise and various operational risks.

• ·Advertising and marketing expenses increased 243.8% YoY to $5.2M.
• ·Impairment expenses of $1.5M in 2025 (none in 2024).
• ·Income tax provision increased to $10.7M in 2025 from $0.6M.
• ·Software license royalties – related parties flat at $24.0M (license fees).

19-03-2026

ONE Group Hospitality, Inc. (STKS) reported in its 2025 10-K filing that combined same-store sales declined 3.7% YTD 2025 vs. 2024, driven by US STK total down 3.7%, Benihana owned down 0.8%, and Grill Concepts total sharply down 12.5%. While US STK managed restaurants showed a 4.2% increase in Q4 and US STK total edged up 0.3% in Q4, most segments experienced consistent YoY declines across quarters, with Grill Concepts non-core down up to 18.0% in Q3 and US STK owned down 6.2% in Q3.

• ·Filing date: March 19, 2026
• ·US STK Owned Restaurants Q3 YoY decline: -6.2%
• ·Grill Concepts Non-Core Owned Restaurants Q3 YoY decline: -18.0%

19-03-2026

AMERICAN BATTERY MATERIALS, INC. reported total assets of $396k as of Dec 31, 2025, up 23% YoY from $323k, driven by higher prepaid expenses, while cash plummeted 73% to $3k. The company posted a net loss of $6.4M for FY2025, worsening 49% YoY from $4.3M amid 19% higher operating expenses and increased other expenses; however, cash used in operations improved to $0.5M from $0.75M. Total liabilities surged 50% to $10.7M, deepening the stockholders' deficit to $10.3M from $6.8M.

• ·All 49,446 warrants expired during 2025.
• ·Weighted average common shares basic and diluted: 2,806,083 (FY2025) vs 2,377,691 (FY2024).
• ·Net loss per share: $(2.30) FY2025 vs $(1.81) FY2024.
• ·Convertible notes payable net: $5.6M (2025) up from $3.9M (2024).

19-03-2026

GENELUX Corp (GNLX) filed its 10-K on March 19, 2026, disclosing it has incurred significant losses since inception, generated no revenue from product sales, and anticipates continued increasing losses without achieving profitability. The company relies on its sole clinical-stage product candidate, Olvi-Vec, in Phase 3 trials for PRROC, but highlights substantial risks including need for additional financing, regulatory delays, manufacturing challenges, and high dependence on this single asset with no approved products. Forward-looking plans involve advancing trials, manufacturing expansion, and hiring, but emphasize uncertainties in commercialization and market acceptance.

• ·Never generated any revenue from commercially approved product sales
• ·Only one product candidate (Olvi-Vec) in clinical development
• ·Highly dependent on key personnel including President, Chief Executive Officer and Chairman

19-03-2026

Mustang Bio, Inc. (MBIO) reported a sharply reduced net loss of $1.9M for the year ended December 31, 2025, compared to $15.8M in 2024, driven by an 85% decline in total operating expenses to $2.4M, primarily from lower R&D expenses ($1.5M credit vs. $8.4M) and elimination of $3.7M asset impairment. Cash and equivalents increased by a net $10.4M, supported by $14.5M from financing activities and reduced operating cash burn of $5.3M (vs. $11.4M prior year), though the company generated no revenue and continues to face drug development risks. General and administrative expenses saw a modest 5% decline to $3.9M.

• ·Other income totaled $0.5M in 2025, up 4% YoY, driven by higher interest income.
• ·Investing activities provided $1.2M cash in 2025 vs. none in 2024.
• ·Financing activities provided $14.5M in 2025 vs. $11.3M in 2024.

19-03-2026

Tigo Energy, Inc. reported net revenue of $103.5M for FY2025, up 91.7% YoY from $54.0M in FY2024, fueled by EMEA (+113.2% to $69.5M) and Americas (+102.0% to $26.5M), while APAC declined 9.2% to $7.5M. Gross profit swung to $44.4M (42.8% margin) from a $4.2M loss, reducing operating loss to $4.5M and net loss to $1.9M from $63.0M, aided by a $14.6M gain on intangible asset sale. However, cost of revenue rose 1.7% to $59.2M, sales & marketing increased 3.0% to $17.4M, G&A up 5.3% to $22.2M, and R&D dipped 6.2% to $9.2M.

• ·Income tax expense increased 485.4% to $603K from $103K.
• ·Interest expense declined 3.6% to $11.0M from $11.4M.
• ·Loss on extinguishment of Convertible Promissory Note: $1.1M in FY2025.

19-03-2026

ACCESS Newswire Inc. reported FY2025 revenue of $22.6M, down 2% YoY from $23.1M, with gross margin slightly improving to $17.3M (77% of revenue) from $17.4M (76%). Operating loss narrowed significantly to $1.9M from $16.3M, primarily due to impairment losses dropping to $0.3M from $14.2M, leading to Adjusted EBITDA growth of 78% to $3.2M; however, net cash from operations fell to $0.6M from $3.2M and free cash flow declined to $0.4M from $2.5M.

• ·Non-GAAP net income FY2025: $2.2M ($0.57 per diluted share) vs FY2024: $0.7M ($0.19 per diluted share).
• ·Adjusted free cash flow FY2025: $1.3M vs FY2024: $2.8M.
• ·Outlook includes expanding products, customer base, newswire distribution, technology investments, strategic acquisitions, and sustainable growth.

19-03-2026

Ollie's Bargain Outlet Holdings, Inc. (OLLI) reported FY2025 net sales of $2.65B, up 16.6% YoY from $2.27B in FY2024, with gross profit increasing 17.3% to $1.07B and net income rising 20.4% to $241M. The company expanded aggressively, opening 86 new stores (vs. 50 prior year) to reach 645 total stores, while comparable store sales grew 3.7% (up from 2.8%). However, product category sales mix remained largely flat YoY, with Consumables steady at 31.9%, Seasonal down slightly to 19.1%, and average net sales per store up modestly 1.3% to $4.3M.

• ·Adjusted EBITDA grew 17.0% YoY to $366M from $313M.
• ·Pre-opening expenses increased to $25.3M from $19.3M.
• ·Company does not expect to pay cash dividends for the foreseeable future.
• ·Board authorized to issue up to 50M shares of undesignated preferred stock without stockholder approval.

19-03-2026

Intellicheck, Inc. reported FY2025 revenues of $22.7M, up 13% YoY from $20.0M, with gross profit rising 13% to $20.5M and net income of $1.3M versus a $0.9M loss in 2024; Adjusted EBITDA surged to $2.6M from $0.5M. However, gross margin slipped slightly to 90.4% from 90.8%, R&D expenses increased 38% to $5.3M, and total operating expenses were essentially flat at $19.4M.

• ·Cash flows from operating activities: $4.5M in FY2025 vs $(2.7M) used in FY2024.
• ·Allowance for credit losses: $157k (2025) vs $100k (2024).
• ·Intangible assets, net: $2.1M (2025) down from $2.4M (2024).
• ·Weighted average basic shares: 19,546,473 (2025) vs 19,327,132 (2024).

19-03-2026

Biofrontera Inc. filed its 10-K on March 19, 2026, disclosing substantial doubt about its ability to continue as a going concern, a history of operating losses, and expectations of ongoing losses without achieving profitability. The company's strategy focuses on expanding U.S. sales of Ameluz combined with RhodoLED Lamps for treating minimally to moderately thick actinic keratosis (AKs) on the face and scalp. Extensive risk factors include heavy dependence on Ameluz, threats from generic competition, manufacturing disruptions, intellectual property lawsuits, reimbursement limitations, and supply chain vulnerabilities from tariffs and geopolitics.

• ·If generic versions of Ameluz enter the market, we may need to reduce the price of Ameluz significantly, which would reduce revenues, and may cause us to lose significant market share.
• ·We are currently and have been involved in intellectual property lawsuits related to our products. Similar suits may also arise in the future.
• ·Our business depends substantially on the success of Ameluz.

19-03-2026

Eton Pharmaceuticals, Inc. highlighted strengths in business development, regulatory expertise via the 505(b)(2) pathway, and established commercial operations in its 10-K filing. Cash flows showed strong improvement with net cash from operating activities rising to $10.5M in 2025 from $1.0M in 2024 (986% YoY increase), and net cash position up $11.0M; however, 2024 saw a large $40.0M investing outflow likely from acquisitions, operating cash declined 86% YoY in 2024 from 2023, and the filing details extensive risks including pricing pressures from the Inflation Reduction Act, regulatory hurdles, competition, and compliance issues.

• ·Team has completed over 150 business development transactions historically.
• ·Filing date: March 19, 2026

19-03-2026

FedEx reported strong revenue growth of 8% YoY to $24B in Q3 FY26 and 6% YoY to $69.7B for the nine months ended Feb 28, 2026, driving net income up 16% YoY to $1.06B quarterly and $2.84B YTD, with diluted EPS rising to $4.41 and $11.91 respectively. However, operating expenses increased across most categories including salaries (+12% YoY quarterly) and purchased transportation (+8% YoY), leading to a slight Q3 operating margin contraction to 5.6% from 5.8% prior year, while YTD margin expanded to 5.6% from 5.2%. Cash and equivalents surged to $8B from $5.5B at May 31, 2025, bolstered by $5.7B operating cash flow (up 25% YoY YTD).

• ·Separation and other costs rose to $202M in Q3 FY26 from $5M YoY.
• ·Business optimization costs declined to $65M in Q3 FY26 from $179M YoY.
• ·Long-term debt increased to $22.8B from $19.2B at May 31, 2025.
• ·Treasury stock repurchases totaled 3.3M shares YTD FY26 vs 8.9M prior year.